Table 4.
Overall survival for B2M mutation status
| Cases | Deaths | Mortality rate/1000 person-years | 5-year survival rate (95% CI) (%) | 10-year survival rate (95% CI) (%) | Unadjusted HR (95% CI) | p valuea | Adjusted HR (95% CI)b, c | p valuea | |
|---|---|---|---|---|---|---|---|---|---|
| B2M mutation status | |||||||||
| B2M wild type | 114 | 38 | 32.5 | 82 (74–88) | 73 (63–80) | Reference | Reference | ||
| B2M mutated | 30 | 8 | 23.7 | 90 (72–97) | 87 (68–95) | 0.75 (0.35–1.60) | 0.5 | 0.65 (0.29–1.48) | 0.3 |
| All | 144 | 46 | 30.5 | 84 (77–89) | 76 (68–82) | – | – | – | – |
HR hazard ratio, CI confidence interval
a
Wald test from cox regression models
b
Adjusted for age at diagnosis, sex, AJCC (American Joint Committee on Cancer) stage and grade
c
Those with unknown AJCC stage or grade included as separate categories under each variable